New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...

Defining combination product CQAs across drug and device enables an end-to-end control strategy that improves product quality ...

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates. In this episode, experts examine combination ...

Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE ...

Congruence between circulating tumor DNA and radiographic response during treatment of advanced sarcoma patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of inhibitor ...

Nerandomilast (PDE4B inhibitor) joined nintedanib and pirfenidone as FDA-approved options, with each demonstrating reduced FVC decline rates in IPF. Clinical benefit is clearest in progressive ...

Pelabresib plus Jakafi significantly reduced spleen volume and improved symptoms in myelofibrosis patients compared to Jakafi alone, with sustained benefits at 96 weeks. The combination therapy showed ...

Drug combination screening is transforming treatment development by focusing on how multiple drugs can work together—rather than relying on a single therapy. This approach allows researchers to ...

Aug 13, 2025, 12:15 PM ETAllurion Technologies Inc. (ALUR) Stock, ALURW StockAI-Generated Earnings Calls Insights ...